Lars Thaning

555 total citations
11 papers, 410 citations indexed

About

Lars Thaning is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lars Thaning has authored 11 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Lars Thaning's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer therapeutics and mechanisms (4 papers). Lars Thaning is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer therapeutics and mechanisms (4 papers). Lars Thaning collaborates with scholars based in Sweden, Norway and United States. Lars Thaning's co-authors include Bengt Bergman, Martin Helsing, Christer Sederholm, Lars Ek, Sverre Sörenson, Roy M. Bremnes, Jan Vilsvik, Ulf Aasebø, Stein Sundstrøm and Andreas Hermes and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Journal of Thoracic Oncology.

In The Last Decade

Lars Thaning

11 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Thaning Sweden 9 263 163 111 105 56 11 410
Susan Robson Switzerland 7 129 0.5× 135 0.8× 96 0.9× 115 1.1× 26 0.5× 17 826
L. Johnetta Blakely United States 11 358 1.4× 156 1.0× 50 0.5× 148 1.4× 114 2.0× 41 579
William Aiken Jamaica 14 151 0.6× 261 1.6× 42 0.4× 90 0.9× 50 0.9× 42 537
Shawgi Sukumaran Australia 11 208 0.8× 60 0.4× 38 0.3× 133 1.3× 48 0.9× 44 407
Omalkhair Abulkhair Saudi Arabia 12 426 1.6× 138 0.8× 45 0.4× 74 0.7× 154 2.8× 28 751
Jennifer Westrup United States 7 268 1.0× 97 0.6× 23 0.2× 47 0.4× 53 0.9× 12 562
Lisa M. Moy United States 11 158 0.6× 84 0.5× 50 0.5× 29 0.3× 31 0.6× 18 329
Lesley Dunfield Canada 8 147 0.6× 94 0.6× 25 0.2× 131 1.2× 67 1.2× 12 487
M. Boccalon Italy 5 431 1.6× 181 1.1× 40 0.4× 195 1.9× 58 1.0× 7 546
April Barbour United States 5 267 1.0× 72 0.4× 40 0.4× 47 0.4× 69 1.2× 7 494

Countries citing papers authored by Lars Thaning

Since Specialization
Citations

This map shows the geographic impact of Lars Thaning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Thaning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Thaning more than expected).

Fields of papers citing papers by Lars Thaning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Thaning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Thaning. The network helps show where Lars Thaning may publish in the future.

Co-authorship network of co-authors of Lars Thaning

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Thaning. A scholar is included among the top collaborators of Lars Thaning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Thaning. Lars Thaning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Koch, Andrea, Bengt Bergman, Erik Holmberg, et al.. (2011). Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. European Journal of Cancer. 47(10). 1546–1555. 48 indexed citations
2.
Nyman, Jan, Signe Friesland, Andreas Hallqvist, et al.. (2008). How to improve loco-regional control in stages IIIa–b NSCLC?. Lung Cancer. 65(1). 62–67. 23 indexed citations
3.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2008). Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology. 26(26). 4261–4267. 124 indexed citations
4.
5.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2007). A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. Journal of Clinical Oncology. 25(18_suppl). 7523–7523. 8 indexed citations
6.
7.
Fernandes, Oswaldo, Lars Thaning, Derek Filbey, et al.. (2003). Prognostic Factors for the Survival of Surgically Treated Patients for Non-Small Cell Lung Cancer. Acta Oncologica. 42(4). 338–341. 11 indexed citations
8.
Helsing, Martin, Lars Thaning, Christer Sederholm, et al.. (1999). Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Lung Cancer. 24(2). 107–113. 9 indexed citations
9.
Westman, Gunnar, Bengt Bergman, M. Albertsson, et al.. (1999). Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer. 35(4). 586–595. 43 indexed citations
10.
11.
Sederholm, Christer, Rolf Lewensohn, V Agrenius, et al.. (1994). A phase II trial of carboplatin (CA) and vindesine (V) in advanced adenocarcinoma of the lung. Lung Cancer. 11. 111–111. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Robson Breakdown of academic impact, for papers by L. Johnetta Blakely Breakdown of academic impact, for papers by William Aiken Breakdown of academic impact, for papers by Shawgi Sukumaran Breakdown of academic impact, for papers by Omalkhair Abulkhair Breakdown of academic impact, for papers by Jennifer Westrup Breakdown of academic impact, for papers by Lisa M. Moy Breakdown of academic impact, for papers by Lesley Dunfield Breakdown of academic impact, for papers by M. Boccalon Breakdown of academic impact, for papers by April Barbour
Rankless by CCL
2026